
Opinion|Videos|December 3, 2025
Non-Cranial Symptoms in GCA
Advertisement
Episodes in this series

This video covers the following questions:
- While patient symptoms often include a new or persistent headache, atypical and non-cranial symptoms also occur. What is your approach to diagnosing GCA when a patient presents these non-cranial symptoms?
Advertisement
Related to this article

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.
Advertisement
Advertisement
Trending on HCPLive
1
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
2
FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCM
3
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
4
Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD
5

